GoodRx (GDRX) Insider Hirsch Douglas Joseph Buys 73,434 Shares

On June 16, 2026, Douglas Hirsch and several other insiders at GoodRx Holdings, Inc. purchased 73,434 shares each. This move suggests a strong vote of confidence in the company's future. Each transaction was not part of a pre-planned trading scheme, reflecting a direct decision by the insiders.

Insider Buying and Selling at GoodRx Holdings, Inc.

Douglas Hirsch wasn't alone in his purchase. Kelly Kennedy, Ronald Bruehlman, Scott Wagner, Agnes Rey-Giraud, and Trevor Bezdek also bought the same number of shares, 73,434 each, on the same day. None of these transactions were pre-planned.

Other Institutional Activity in GoodRx Holdings

Francisco Partners Management kept its stake steady at 60,078,184 shares, valued at approximately $117.8 million. LSV Asset Management increased its holdings significantly by 2,156,031 shares, bringing its total to 4,981,931 shares worth about $9.8 million. Ameriprise Financial added 1,183,329 shares, ending with 4,455,760 shares valued at $8.7 million. Vanguard Capital Management and Vanguard Portfolio Management both initiated positions, each acquiring over 3.3 million shares, valued at $8.4 million and $6.6 million, respectively.

GoodRx Holdings, Inc. Stock Down 22.8%

Shares of NasdaqGS:GDRX are trading around $2.73. GoodRx Holdings, Inc. has a market capitalization of roughly $924.6 million. The company trades with a P/E ratio of 45.5 and a forward P/E of 7.6, indicating potential growth. The stock has a beta of 1.615, suggesting higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from $1.77 to $5.81. It has a 50-day moving average of $2.54 and a 200-day moving average of $2.89.

Analysts Set New Price Targets

On May 14, 2026, Citigroup maintained its 'buy' rating on GoodRx, setting a price target of $4.00. Similarly, TD Cowen upheld its 'buy' rating with the same target on May 11, 2026. Wells Fargo also maintained a 'buy' rating but with a slightly lower target of $3.50. The consensus among 13 analysts is a 'hold' rating, with an average price target of $3.18.

About GoodRx Holdings, Inc.

GoodRx Holdings, Inc., headquartered in Santa Monica, California, operates in the healthcare sector, specifically in health information services. The company offers a platform that helps consumers compare prescription drug prices to save money. Beyond its price comparison services, GoodRx provides subscription programs, telehealth services, and solutions for pet healthcare. With a team of 697 employees, GoodRx continues to facilitate connections between consumers and pharmacies through its network.

Bottom Line

The recent insider buying at GoodRx Holdings by Douglas Hirsch and others suggests confidence in the company's prospects. While the stock trades at a modest price, institutional activity shows varied interest levels, with some funds increasing their positions. Analysts remain mixed, with a consensus hold rating, but some see potential upside.